Enhancing Prodrug Solubility with Syngene’s SynVent Platform
Prodrugs are medications that, once administered, are metabolized in the body to release the active ingredient. They help to improve a medication’s effectiveness and can in some cases avoid certain side effects or toxicities.
SynWeave™ : Redefining Cell Line Development for Next-Generation Biologics
The biopharmaceutical industry witnessed significant innovation, with many new recombinant protein therapeutics receiving FDA approval. However, these therapies are often costly, emphasizing the need for greater efficiency and productivity.
Powering Global Pharma Innovation: The Rise of Indian CROs
India supplies more than 20% of the world’s generic medicines, reaching over 200 countries. It provides 40% of generic drugs used in the U.S. and 80% of antiretrovirals globally, reinforcing its pivotal role in affordable global healthcare.
Peptides: A Scientific Revolution in Modern Medicine
Learn about GLP-1 peptides and their revolutionary impact on modern medicine, and how Syngene is enabling this advancement through its state-of-the-art peptide synthesis facility.
The Syngene Advantage: Accelerating Progress Through Integrated Technology Transfer
At Syngene, technology transfer is a seamless, cross-site collaboration, accelerating your journey from concept to commercialization. This video showcases the synergy between our Bangalore (BSEZ) and Mangalore (MSEZ) campuses, driven by robust systems and deep expertise. Our facilities are built for uncompromising quality, proudly GMP certified, 21 CFR compliant, and USFDA approved, ensuring global standards […]
Solving Prep-HPLC Challenges in Early Drug Discovery: Efficient Purification of Unstable Prodrugs via C18 SPE
In the fast-paced world of drug discovery, every day counts—and so does every drop of solvent. Yet for chemists working with polar, unstable prodrugs and new chemical entities (NCEs), one critical step has remained frustratingly slow, expensive, and inefficient: purification.
From Fragile to Agile: Strategic imperatives for strengthening biopharma supply chains
In today’s rapidly evolving world, a resilient supply chain is no longer optional for the biopharma industry; it’s a strategic necessity.
Chiral Inversion Analysis for a Clinical-Stage Biopharmaceutical Company
Learn how Syngene enabled chiral inversion analysis through integrated in vitro and in vivo studies, delivering high-quality data that advanced drug development for a targeted protein degradation program.
Preparation and in-vitro ADME assays screening for rac-Rotigotine prodrugs towards alleviating PD/restless leg syndrome
Learn how Syngene customized ADME assays to identify rac-Rotigotine prodrugs with enhanced bioavailability, which could be used for treating Parkinson’s disease and restless leg syndrome.
Overcoming ADME Challenges in PROTAC Development: Key Insights from Syngene Experts
Targeted protein degraders like PROTACs offer novel therapeutic potential but face ADME hurdles—poor solubility, permeability, and weak IVIVC. Experts Prasoon Chaturvedi (C4 Therapeutics), Vishwottam Kandikere, and Amol Raje (Syngene) discussed solutions.